Human Umbilical Cord Blood Plasma-Derived Exosomal miR-410-3p Alleviates Liver Injury by Regulating the Mitochondria-Mediated Antiapoptotic Signaling

Abstract

Severe liver injury is a life-threatening condition with high mortality and limited therapeutic options. Extensive research on heterochronic parabiosis has highlighted the potent regenerative repair capabilities of young blood in tissue regeneration. However, it remains unclear whether younger blood, specifically umbilical cord blood, can offer similar benefits for tissue repair. In this study, we demonstrate that exosomes derived from umbilical cord blood plasma (CBP-Exos) exhibit significant therapeutic effects in both acute and chronic liver injury models, outperforming exosomes from young peripheral blood plasma. Treatment with CBP-Exos notably reduced liver necrosis, lipid peroxidation, and apoptosis in liver tissues of acute liver injury (ALI) mice. Mechanistically, miR-410-3p, derived from CBP-Exos, directly targets the proapoptotic gene Bim for posttranscriptional degradation. The downregulation of Bim facilitates the activation of mitochondrial-mediated Bcl2-CytoC antiapoptotic signaling, resulting in the restoration of mitochondrial structure and function, thereby inhibiting hepatocyte apoptosis and oxidative stress. Furthermore, overexpression of miR-410-3p significantly improved liver function in ALI mice. These findings identify the therapeutic effects of CBP-Exos are attributed to the miR-410-3p/Bcl2/CytoC axis, laying a foundation for the clinical application of CBP-Exos and miR-410-3p in liver diseases.

Keywords

apoptosis / exosome / human umbilical cord blood plasma / liver injury / miR-410-3p / mitochondria

References

[1] H. Devarbhavi, S. K. Asrani, J. P. Arab, Y. A. Nartey, E. Pose, and P. S. Kamath, “Global Burden of Liver Disease: 2023 Update,” Journal of Hepatology 79, no. 2 (2023): 516-537.

[2] R. J. Andrade, N. Chalasani, E. S. Björnsson, et al., “Drug-Induced Liver Injury,” Nature Reviews Disease primers 5, no. 1 (2019): 58.

[3] E. Björnsson and J. Hoofnagle, “Categorization of Drugs Implicated in Causing Liver Injury: Critical Assessment Based on Published Case Reports,” Hepatology (Baltimore, Md) 63, no. 2 (2016): 590-603.

[4] A. Kumachev and P. E. Wu, “Drug-Induced Liver Injury,” Canadian Medical Association Journal 193, no. 9 (2021): E310.

[5] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-Induced Liver Injury. Journal of Hepatology 70, no. 6 (2019): 1222-1261.

[6] M. J. Conboy, I. M. Conboy, and T. A. Rando, “Heterochronic Parabiosis: Historical Perspective and Methodological Considerations for Studies of Aging and Longevity,” Aging Cell 12, no. 3 (2013): 525-530.

[7] S. Ma, S. Wang, Y. Ye, et al., “Heterochronic Parabiosis Induces Stem Cell Revitalization and Systemic Rejuvenation Across Aged Tissues,” Cell Stem Cell 29, no. 6 (2022): 990-1005.e1010.

[8] J. M. Castellano, K. I. Mosher, R. J. Abbey, et al., “Human Umbilical Cord Plasma Proteins Revitalize Hippocampal Function in Aged Mice,” Nature 544, no. 7651 (2017): 488-492.

[9] A. B. Schroer, P. B. Ventura, J. Sucharov, et al., “Platelet Factors Attenuate Inflammation and Rescue Cognition in Ageing,” Nature 620, no. 7976 (2023): 1071-1079.

[10] B. Zhang, D. E. Lee, A. Trapp, et al., “Multi-Omic Rejuvenation and Life Span Extension on Exposure to Youthful Circulation,” Nature Aging 3, no. 8 (2023): 948-964.

[11] M. A. Iafolla, J. Tay, and D. S. Allan, “Transplantation of Umbilical Cord Blood-Derived Cells for Novel Indications in Regenerative Therapy or Immune Modulation: A Scoping Review of Clinical Studies,” Biology of Blood and Marrow Transplantation 20, no. 1 (2014): 20-25.

[12] D. Ilic, C. Miere, and E. Lazic, “Umbilical Cord Blood Stem Cells: Clinical Trials in Non-Hematological Disorders,” British Medical Bulletin 102 (2012): 43-57.

[13] T. H. Jaing, “Umbilical Cord Blood: A Trustworthy Source of Multipotent Stem Cells for Regenerative Medicine,” Cell Transplantation 23, no. 4-5 (2014): 493-496.

[14] L. Zhao, G. Cheng, K. Choksi, et al., “Transplantation of Human Umbilical Cord Blood-Derived Cellular Fraction Improves Left Ventricular Function and Remodeling After Myocardial Ischemia/Reperfusion,” Circulation Research 125, no. 8 (2019): 759-772.

[15] C. Lang, X. Shu, L. Peng, and X. Yu, “The ERK Signaling Pathway Is Involved in Cardiotrophin-1-Induced Neural Differentiation of Human Umbilical Cord Blood Mesenchymal Stem Cells in Vitro,” Cytotechnology 71, no. 5 (2019): 977-988.

[16] R. Stiner, M. Alexander, G. Liu, et al., “Transplantation of Stem Cells From Umbilical Cord Blood as Therapy for Type I Diabetes,” Cell and Tissue Research 378, no. 2 (2019): 155-162.

[17] F. Yin, W. Y. Wang, and W. H. Jiang, “in vitroHuman Umbilical Cord Mesenchymal Stem Cells Ameliorate Liver Fibrosis and : From Biological Characteristics to Therapeutic Mechanisms,” World Journal of Stem Cells 11, no. 8 (2019): 548-564.

[18] X. Yang, Y. Meng, Z. Han, F. Ye, L. Wei, and C. Zong, “Mesenchymal Stem Cell Therapy for Liver Disease: Full of Chances and Challenges,” Cell & Bioscience 10 (2020): 123.

[19] A. Habib, H. Hou, T. Mori, et al., “Human Umbilical Cord Blood Serum-Derived α-Secretase: Functional Testing in Alzheimer's Disease Mouse Models,” Cell Transplantation 27, no. 3 (2018): 438-455.

[20] D. J. Eve, J. Ehrhart, T. Zesiewicz, et al., “Plasma Derived From Human Umbilical Cord Blood Modulates Mitogen-Induced Proliferation of Mononuclear Cells Isolated From the Peripheral Blood of ALS Patients,” Cell Transplantation 25, no. 5 (2016): 963-971.

[21] Y. A. Romanov, V. V. Vtorushina, T. N. Dugina, A. Y. Romanov, and N. V. Petrova, “Human Umbilical Cord Blood Serum/Plasma: Cytokine Profile and Prospective Application in Regenerative Medicine,” Bulletin of Experimental Biology and Medicine 168, no. 1 (2019): 173-177.

[22] R. Kalluri and V. LeBleu, “The Biology Function and Biomedical Applications of Exosomes,” Science (New York, NY) 367, no. 6478 (2020).

[23] R. Kalluri and V. S. LeBleu, “The Biology, Function, and Biomedical Applications of Exosomes,” Science 367, no. 6478 (2020): eaau6977.

[24] Y. Lee and J. H. Kim, “The Emerging Roles of Extracellular Vesicles as Intercellular Messengers in Liver Physiology and Pathology,” Clinical and Molecular Hepatology 28, no. 4 (2022): 706-724.

[25] X. Chen, Y. Luo, Q. Zhu, et al., “Small Extracellular Vesicles From Young Plasma Reverse Age-Related Functional Declines by Improving Mitochondrial Energy Metabolism,” Nature Aging 4, no. 6 (2024): 814-838.

[26] L. Chen, R. Chen, S. Kemper, M. Cong, H. You, and D. R. Brigstock, “Therapeutic Effects of Serum Extracellular Vesicles in Liver Fibrosis,” Journal of Extracellular Vesicles 7, no. 1 (2018): 1461505.

[27] W. Yang, N. Ding, R. Luo, et al., “Exosomes From Young Healthy Human Plasma Promote Functional Recovery From Intracerebral Hemorrhage via Counteracting Ferroptotic Injury,” Bioactive Materials 27 (2023): 1-14.

[28] L. Jia, X. Zhou, X. Huang, et al., “Maternal and Umbilical Cord Serum-Derived Exosomes Enhance Endothelial Cell Proliferation and Migration,” The FASEB Journal 32, no. 8 (2018): 4534-4543.

[29] K. Liu, B. Gong, T. Li, et al., “Bioactive Self-Healing Umbilical Cord Blood Exosomes Hydrogel for Promoting Chronic Diabetic Wound Healing,” Biochemical and Biophysical Research Communications 690 (2024): 149241.

[30] X. Q. Zhong, D. Wang, S. Chen, et al., “Umbilical Cord Blood-Derived Exosomes From Healthy Term Pregnancies Protect Against Hyperoxia-Induced Lung Injury in Mice,” Clinical and Translational Science 16, no. 6 (2023): 966-977.

[31] F. B. Lu, D. Z. Chen, L. Chen, et al., “Attenuation of Experimental Autoimmune Hepatitis in Mice With Bone Mesenchymal Stem Cell-Derived Exosomes Carrying MicroRNA-223-3p,” Molecules and Cells 42, no. 12 (2019): 906-918.

[32] M. O. El-Derany and S. G. AbdelHamid, “Upregulation of miR-96-5p by Bone Marrow Mesenchymal Stem Cells and Their Exosomes Alleviate Non-Alcoholic Steatohepatitis: Emphasis on Caspase-2 Signaling Inhibition,” Biochemical Pharmacology 190 (2021): 114624.

[33] J. Kim, C. Lee, Y. Shin, et al., “sEVs From Tonsil-Derived Mesenchymal Stromal Cells Alleviate Activation of Hepatic Stellate Cells and Liver Fibrosis Through miR-486-5p,” Molecular Therapy 29, no. 4 (2021): 1471-1486.

[34] Z. Du, T. Wu, L. Liu, B. Luo, and C. Wei, “Extracellular Vesicles-Derived miR-150-5p Secreted by Adipose-Derived Mesenchymal Stem Cells Inhibits CXCL1 Expression to Attenuate Hepatic Fibrosis,” Journal of Cellular and Molecular Medicine 25, no. 2 (2021): 701-715.

[35] M. Shao, Q. Xu, Z. Wu, et al., “Exosomes Derived From Human Umbilical Cord Mesenchymal Stem Cells Ameliorate IL-6-Induced Acute Liver Injury Through miR-455-3p,” Stem Cell Research & Therapy 11, no. 1 (2020): 37.

[36] M. Charni-Natan and I. Goldstein, “Protocol for Primary Mouse Hepatocyte Isolation,” STAR Protocols 1, no. 2 (2020): 100086.

[37] M. Domart, D. Esposti, M. Sebagh, et al., “Concurrent Induction of Necrosis, Apoptosis, and Autophagy in Ischemic Preconditioned Human Livers Formerly Treated by Chemotherapy,” Journal of Hepatology 51, no. 5 (2009): 881-889.

[38] F. J. Bock and S. W. G. Tait, “Mitochondria as Multifaceted Regulators of Cell Death,” Nature Reviews Molecular Cell Biology 21, no. 2 (2020): 85-100.

[39] X. Wang, Y. He, B. Mackowiak, and B. Gao, “MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in Liver Diseases,” Gut 70, no. 4 (2021): 784-795.

[40] M. Zheng, R. Karki, P. Vogel, and T. D. Kanneganti, “Caspase-6 Is a Key Regulator of Innate Immunity, Inflammasome Activation, and Host Defense,” Cell 181, no. 3 (2020): 674-687.e613.

[41] L. Galluzzi, A. López-Soto, S. Kumar, and G. Kroemer, “Caspases Connect Cell-Death Signaling to Organismal Homeostasis,” Immunity 44, no. 2 (2016): 221-231.

[42] R. Singh, A. Letai, and K. Sarosiek, “Regulation of Apoptosis in Health and Disease: The Balancing Act of BCL-2 Family Proteins,” Nature Reviews Molecular Cell Biology 20, no. 3 (2019): 175-193.

[43] F. Heymann and F. Tacke, “Immunology in the Liver-From Homeostasis to Disease. Nature Reviews,” Gastroenterology & Hepatology 13, no. 2 (2016): 88-110.

[44] S. K. Asrani, H. Devarbhavi, J. Eaton, and P. S. Kamath, “Burden of Liver Diseases in the World,” Journal of Hepatology 70, no. 1 (2019): 151-171.

[45] J. D. Yang, P. Hainaut, G. J. Gores, A. Amadou, A. Plymoth, and L. R. Roberts, “A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management,” Nature Reviews Gastroenterology & Hepatology 16, no. 10 (2019): 589-604.

[46] E. A. Tsochatzis, J. Bosch, and A. K. Burroughs, “Liver Cirrhosis,” Lancet 383, no. 9930 (2014): 1749-1761.

[47] A. Psaraki, L. Ntari, C. Karakostas, D. Korrou-Karava, and M. G. Roubelakis, “Extracellular Vesicles Derived From Mesenchymal Stem/Stromal Cells: The Regenerative Impact in Liver Diseases,” Hepatology 75, no. 6 (2022): 1590-1603.

[48] F. Lin, W. Chen, J. Zhou, et al., “Mesenchymal Stem Cells Protect Against Ferroptosis via Exosome-Mediated Stabilization of SLC7A11 in Acute Liver Injury,” Cell Death & Disease 13, no. 3 (2022): 271.

[49] S. Bruno, C. Pasquino, M. B. Herrera Sanchez, “HLSC-Derived Extracellular Vesicles Attenuate Liver Fibrosis and Inflammation in a Murine Model of Non-Alcoholic Steatohepatitis,” Molecular Therapy 28, no. 2 (2020): 479-489.

[50] K. McDaniel, N. Wu, T. Zhou, et al., “Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA,” Hepatology 69, no. 6 (2019): 2562-2578.

[51] R. Wu, X. Fan, Y. Wang, “Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy,” Frontiers in Immunology 13 (2022): 833878.

[52] N. S. Holman, R. J. Church, M. Nautiyal, et al., “Hepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury,” Toxicological Sciences 170, no. 2 (2019): 499-508.

[53] X. Li, R. Chen, S. Kemper, and D. R. Brigstock, “Extracellular Vesicles From Hepatocytes Are Therapeutic for Toxin-Mediated Fibrosis and Gene Expression in the Liver,” Frontiers in Cell and Developmental Biology 7 (2019): 368.

[54] M. Alhomrani, J. Correia, M. Zavou, et al., “The Human Amnion Epithelial Cell Secretome Decreases Hepatic Fibrosis in Mice With Chronic Liver Fibrosis,” Frontiers in Pharmacology 8 (2017): 748.

[55] J. Li, W. Liu, J. Zhang, and C. Sun, “The Role of Mitochondrial Quality Control in Liver Diseases: Dawn of a Therapeutic Era,” International Journal of Biological Sciences 21, no. 4 (2025): 1767-1783.

[56] H. Han, R. Desert, S. Das, et al., “Danger Signals in Liver Injury and Restoration of Homeostasis,” Journal of Hepatology 73, no. 4 (2020): 933-951.

[57] E. Kostallari, S. Valainathan, L. Biquard, V. H. Shah, and P. E. Rautou, “Role of Extracellular Vesicles in Liver Diseases and Their Therapeutic Potential,” Advanced Drug Delivery Reviews 175 (2021): 113816.

[58] Y. Jin, J. Wang, H. Li, et al., “Extracellular Vesicles Secreted by Human Adipose-Derived Stem Cells (hASCs) Improve Survival Rate of Rats With Acute Liver Failure by Releasing lncRNA H19,” EBioMedicine 34 (2018): 231-242.

[59] J. Zheng, T. Lu, C. Zhou, et al., “Extracellular Vesicles Derived From Human Umbilical Cord Mesenchymal Stem Cells Protect Liver Ischemia/Reperfusion Injury by Reducing CD154 Expression on CD4+ T Cells via CCT2,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 7, no. 18 (2020): 1903746.

[60] Y. Yan, W. Jiang, Y. Tan, et al., “hucMSC Exosome-Derived GPX1 Is Required for the Recovery of Hepatic Oxidant Injury,” Molecular Therapy: The Journal of the American Society of Gene Therapy 25, no. 2 (2017): 465-479.

[61] L. Li, Y. Liu, K. Wang, et al., “Stem Cell Exosomes: New Hope and Future Potential for Relieving Liver Fibrosis,” Clinical and Molecular Hepatology 31, no. 2 (2025): 333-349.

[62] G. Lou, Z. Chen, M. Zheng, and Y. Liu, “Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Strategy for Liver Diseases,” Experimental & Molecular Medicine 49, no. 6 (2017): e346.

[63] A. Chowdhury, A. Santra, K. Bhattacharjee, S. Ghatak, D. R. Saha, and G. K. Dhali, “Mitochondrial Oxidative Stress and Permeability Transition in Isoniazid and Rifampicin Induced Liver Injury in Mice,” Journal of Hepatology 45, no. 1 (2006): 117-126.

[64] T. Lu, J. Zhang, J. Cai, et al., “Extracellular Vesicles Derived From Mesenchymal Stromal Cells as Nanotherapeutics for Liver Ischaemia-Reperfusion Injury by Transferring Mitochondria to Modulate the Formation of Neutrophil Extracellular Traps,” Biomaterials 284 (2022): 121486.

[65] Y. Yan, W. Jiang, Y. Tan, et al., “hucMSC Exosome-Derived GPX1 Is Required for the Recovery of Hepatic Oxidant Injury,” Molecular Therapy 25, no. 2 (2017): 465-479.

[66] W. Yan, D. Li, T. Chen, G. Tian, P. Zhou, and X. Ju, “Umbilical Cord MSCs Reverse D-Galactose-Induced Hepatic Mitochondrial Dysfunction via Activation of Nrf2/HO-1 Pathway,” Biological & Pharmaceutical Bulletin 40, no. 8 (2017): 1174-1182.

[67] Q. Xiao, Y. Zhao, L. Ma, and R. Piao, “Orientin Reverses Acetaminophen-Induced Acute Liver Failure by Inhibiting Oxidative Stress and Mitochondrial Dysfunction,” Journal of Pharmacological Sciences 149, no. 1 (2022): 11-19.

[68] J. Zhou, Y. Zhang, S. Li, et al., “Dendrobium Nobile Lindl. Alkaloids-Mediated Protection Against CCl(4-)Induced Liver Mitochondrial Oxidative Damage Is Dependent on the Activation of Nrf2 Signaling Pathway,” Biomedicine & Pharmacotherapy 129 (2020): 110351.

[69] D. Chen, H. M. Ni, L. Wang, et al., “p53 Up-Regulated Modulator of Apoptosis Induction Mediates Acetaminophen-Induced Necrosis and Liver Injury in Mice,” Hepatology 69, no. 5 (2019): 2164-2179.

[70] S. Victorelli, H. Salmonowicz, J. Chapman, et al., “Apoptotic Stress Causes mtDNA Release During Senescence and Drives the SASP,” Nature 622, no. 7983 (2023): 627-636.

[71] C. Chakraborty, A. R. Sharma, G. Sharma, and S. S. Lee, “Therapeutic Advances of miRNAs: A Preclinical and Clinical Update,” Journal of Advanced Research 28 (2021): 127-138.

[72] J. Song, J. Wang, K. Liu, W. Xu, T. Sun, and J. Liu, “The Role of microRNAs in Erectile Dysfunction: From Pathogenesis to Therapeutic Potential,” Front Endocrinol (Lausanne) 13 (2022): 1034043.

[73] J. Hanna, G. S. Hossain, and J. Kocerha, “The Potential for microRNA Therapeutics and Clinical Research,” Frontiers in Genetics 10 (2019): 478.

[74] S. Rallapalli, S. Guhathakurta, S. Narayan, D. K. Bishi, V. Balasubramanian, and P. S. Korrapati, “Generation of Clinical-Grade Red Blood Cells From Human Umbilical Cord Blood Mononuclear Cells,” Cell and Tissue Research 375, no. 2 (2019): 437-449.

[75] J. A. Brown and V. A. Boussiotis, “Umbilical Cord Blood Transplantation: Basic Biology and Clinical Challenges to Immune Reconstitution,” Clinical Immunology 127, no. 3 (2008): 286-297.

[76] D. C. Hernández, K. Juelke, N. C. Müller, et al., “An in Vitro Platform Supports Generation of Human Innate Lymphoid Cells From CD34(+) Hematopoietic Progenitors That Recapitulate Ex Vivo Identity,” Immunity 54, no. 10 (2021): 2417-2432.e2415.

[77] Y. H. Lee, “The Role of Cord Blood Banks in the Cell Therapy Era: Future Perspectives,” Blood Research 52, no. 3 (2017): 153-156.

[78] V. Lo Presti, S. Nierkens, J. J. Boelens, and N. P. van Til, “Use of Cord Blood Derived T-Cells in Cancer Immunotherapy: Milestones Achieved and Future Perspectives,” Expert Review of Hematology 11, no. 3 (2018): 209-218.

[79] W. Young, “Plasma-Depleted Versus Red Cell-Reduced Umbilical Cord Blood,” Cell Transplantation 23 (2014): 407-415.

[80] S. Roura, J. M. Pujal, C. Gálvez-Montón, and A. Bayes-Genis, “The Role and Potential of Umbilical Cord Blood in an Era of New Therapies: A Review,” Stem Cell Research & Therapy 6, no. 1 (2015): 123.

[81] S. Roura and J. Vives, “Extracellular Vesicles: Squeezing Every Drop of Regenerative Potential of Umbilical Cord Blood,” Metabolism: Clinical and Experimental 95 (2019): 102-104.

[82] J. Y. Lee, J. P. Tuazon, J. Ehrhart, P. R. Sanberg, and C. V. Borlongan, “Gutting the Brain of Inflammation: A Key Role of Gut Microbiome in Human Umbilical Cord Blood Plasma Therapy in Parkinson's Disease Model,” Journal of Cellular and Molecular Medicine 23, no. 8 (2019): 5466-5474.

[83] L. Jia, X. Zhou, X. Huang, et al., “Maternal and Umbilical Cord Serum-Derived Exosomes Enhance Endothelial Cell Proliferation and Migration,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 32, no. 8 (2018): 4534-4543.

[84] Y. Hu, S. S. Rao, Z. X. Wang, et al., “Exosomes From Human Umbilical Cord Blood Accelerate Cutaneous Wound Healing Through miR-21-3p-Mediated Promotion of Angiogenesis and Fibroblast Function,” Theranostics 8, no. 1 (2018): 169-184.

[85] T. T. Li, Y. H. Luo, H. Yang, et al., “FBXW5 Aggravates Hepatic Ischemia/Reperfusion Injury via Promoting Phosphorylation of ASK1 in a TRAF6-Dependent Manner,” International Immunopharmacology 99 (2021): 107928.

[86] Z. Huang, T. Mou, Y. Luo, et al., “Inhibition of miR-450b-5p Ameliorates Hepatic Ischemia/Reperfusion Injury via Targeting CRYAB,” Cell Death & Disease 11, no. 6 (2020): 455.

[87] B. Yang, L. Lu, T. Xiong, et al., “The Role of Forkhead Box M1-Methionine Adenosyltransferase 2 A/2B Axis in Liver Inflammation and Fibrosis,” Nature Communications 15, no. 1 (2024): 8388.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.